Q-omics provides the consensus-scored CLEC18B profile across patient tissues and cancer cell-line models. CLEC18B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CLEC18B is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, CLEC18B RNA expression shows 12,094 significant gene co-expression associations, with the highest sampling consensus in SKCM. Together, these results highlight KIRC, KIRP, and SKCM as cancer lineages where CLEC18B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLEC18B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLEC18B survival associations across molecular data types. CLEC18B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLEC18B RNA expression–survival associations across cancer types. High CLEC18B expression shows unfavorable associations in LGG and GBM, but favorable associations in KIRC, SCLC, BLCA and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CLEC18B RNA expression.
This table summarizes CLEC18B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CLEC18B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLEC18B shows lower tumor expression in KIRP and KICH and higher tumor expression in KIRC, COAD, UCEC and LUSC. The KIRP box plot shows higher CLEC18B RNA expression in normal versus tumor tissue (log2 FC = −2.444, t-test p < 0.001).
This table shows molecular features associated with CLEC18B in patient tissues and cancer cell lines. In patient samples, CLEC18B shows the broadest associations at the RNA and protein expression levels, with SKCM recurring as the lineage with the largest associated feature set. In cancer cell lines, CLEC18B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
